Search
The Drug Discovery Unit has been finding ways for smart drugs to penetrate deep into cells and attacking their disease targets while causing fewer side effects
It is now known that the HOX11 gene is permanently activated in the leukaemia cells and it drives the disease.
A cutting edge cancer imaging facility will help specialist children's cancer researchers at Perth's Telethon Institute for Child Health Research.
Avantogen Limited (ACU:ASX) today announced that cancer researchers at Perth's The Kids for Child Health Research (TICHR) and Avantogen Limited
A national study is investigating diet, chemical exposure and genetic factors in a new bid to unravel the causes of childhood leukaemia.
West Australian families are being asked to play a vital role in a major new national study to unravel the causes of childhood leukaemia.
Citation: Sek K, Chen AXY, Cole T, Armitage JD, Tong J, ……… Waithman J, Parish IA, et al. Tumor site-directed A1R expression enhances CAR T cell
Acute lymphoblastic leukaemia is a highly heterogeneous malignancy characterised by various genomic alterations that influence disease progression and therapeutic outcomes. Gene fusions involving the immunoglobulin heavy chain gene represent a complex and diverse category.
Gliomas are the most common type of malignant primary central nervous system (CNS) tumors, resulting in significant morbidity and mortality in children and adolescent and young adult (AYA) patients. The discovery of mutations in isocitrate dehydrogenase (IDH) genes has dramatically changed the classification and understanding of gliomas. IDH mutant gliomas have distinct clinical, pathological, and molecular features including a favorable prognosis and response to therapy compared to their wildtype counterparts.
Several studies have established that patients with localized perinatal neuroblastoma can be safely observed; however, long-term outcomes have not been previously reported. We evaluated long-term outcomes of infants with suspected perinatal neuroblastoma enrolled on the Children's Oncology Group ANBL00P2, which included an expectant observation approach.